Original observations reported in our study include the comparative evaluation of HCC risk after a balanced match between DAA-treated and untreated participants by propensity analysis according to demographic and virological data (age, sex, genotype HCV-3), as well as clinical variables serving as surrogate markers of liver function (bilirubin, platelet count, albumin, INR, creatinine and a history of previous decompensation), which are used in order to evaluate the effect of viral eradication and liver disease stage on the risk of HCC occurrence. This evidence concerns the gene ALB and hepatocellular carcinoma.